BIO (BIO) vs. TMO and DHR: Can Activist Pressure Close Bio-Rad’s Valuation Discount?

insidermonkey.com · 2026-10-27

Is BIO a good stock to buy? We came across a bullish thesis on Bio-Rad Laboratories, Inc. on One Idea Per Day’s Substack by Paul.

TickrTrends take: Bio-Rad Laboratories trades at a valuation discount compared to peers TMO and DHR, a gap that activist pressure may attempt to narrow through operational or strategic changes. TickrTrends currently assesses BIO as overvalued despite this discount, suggesting the stock's current price may not adequately reflect underlying fundamentals or risks in the Healthcare sector. Investors focused on valuation metrics should monitor whether activist involvement produces meaningful improvements in profitability or growth rates that could justify any narrowing of the peer valuation gap.

Read the full story at insidermonkey.com →